Explainer
Homosalate and sunscreen filters: what the EU changed
Since 1 July 2025, EU shelves should hold no body sunscreen with homosalate, and face products are capped at 7.34%. That is not a ban and not a verdict that the filter is toxic. It is a recalculated safety margin. Here is what regulators decided, how the US reads the same filters, and what to do with the bottle you already own.
Revelika editors9 min read
What the EU decided
Homosalate is one of the most familiar chemical filters in sunscreen. From 2009 the EU allowed it in any cosmetic product at up to 10% 6. Commission Regulation (EU) 2022/2195 of 10 November 2022 rewrote that line of Annex VI: homosalate is now permitted only in face products, excluding propellant sprays, at no more than 7.34% 1. Body lotions, body sprays, after-sun and hand creams are off the table.
The switch was phased. Non-compliant products could not be placed on the EU market from 1 January 2025, and could no longer be sold from 1 July 2025 1. Homosalate got a longer runway than the other substances in the same regulation, and the Commission says why: reformulating a sunscreen is technically difficult, and every change of filter means testing the SPF again 1.
The 7.34% figure has a paper trail. In June 2021 the EU’s Scientific Committee on Consumer Safety (SCCS) concluded that homosalate was not safe at up to 10%, and safe only up to 0.5% in the finished product 2. Industry asked for a recalculation covering face products alone; in December 2021 the SCCS answered that up to 7.34% in face cream and pump spray was safe 3. The Commission noted that combining 0.5% in everything with 7.34% in face products would again push the margin of safety below 100, so it chose the face-only option 1. Homosalate was not banned: it stays where the arithmetic works, in face products.
Why: a margin of safety, not “toxic”
EU cosmetic safety assessment rests on one ratio, the margin of safety (MoS). On top is a dose at which laboratory animals show little or no effect; underneath is how much of the substance reaches a person’s bloodstream each day. For systemic effects the SCCS wants a margin of at least 100.
For homosalate the starting point was a LOAEL of 60 mg/kg body weight per day from a rat study run to OECD guideline 422, which combines repeated dosing with a reproductive toxicity screen. Adjusting from a LOAEL to a NOAEL and assuming 50% oral bioavailability gave 10 mg/kg per day 2. Then the consumer scenario: 18 g of sunscreen on the body daily, 10% homosalate, 5.3% passing through skin, a 60 kg adult. That yields a systemic dose of 1.59 mg/kg per day and a margin of 6.3 against the 100 required 2. To reach 100, a sunscreen alone could hold at most 0.63% homosalate; counting face and hand creams too, 0.5% 2.
Where do hormones come in? They triggered the review: in 2019 the Commission issued a call for data over homosalate’s potential endocrine-disrupting properties 1. But the SCCS itself judged the evidence for endocrine activity “inconclusive, and at best equivocal”, and declined to derive an endocrine-specific point of departure from it 2. The limit, in other words, comes from conventional toxicology and exposure modelling. The new limit is the product of exposure arithmetic, not of demonstrated harm in people.
Not just homosalate: oxybenzone and octocrylene
Homosalate came in the second wave. The first, Regulation (EU) 2022/1176 of 7 July 2022, covered oxybenzone (Benzophenone-3) and octocrylene, again citing potential endocrine properties and SCCS opinions 4. It was not oxybenzone’s first cut: in 2017 its ceiling fell from 10% to 6% 7. Now 6% applies only to face, hand and lip products (not sprays); body products, sprays included, are capped at 2.2%, and everything else at 0.5% 4. Octocrylene kept 10%, except in propellant sprays, where the cap is 9% 4. Products made to the old rules could be placed on the market until 28 January 2023 and sold until 28 July 2023 4.
| Filter (INCI) | Before | Now | Applies from |
|---|---|---|---|
| Homosalate | 10% in any product 6 | 7.34%, face products only, excluding propellant sprays 1 | placing on market: 1 Jan 2025; sale: 1 Jul 2025 1 |
| Benzophenone-3 (oxybenzone) | 6% (since 2017; 10% before that) 7 | face, hand, lip, no sprays: 6%; body incl. sprays: 2.2%; other: 0.5% 4 | old-rule products placed until 28 Jan 2023, sold until 28 Jul 2023 4 |
| Octocrylene | 10% 6 | propellant sprays: 9%; other: 10% 4 | same dates as oxybenzone 4 |
Set against this, the European filter palette looks different from the American one. The EU has long allowed filters the US did not: Tinosorb S at up to 10%, avobenzone at up to 5% 5. Avobenzone covers UVA well but breaks down in light on its own. In a 2001 lab study, Tinosorb S protected avobenzone from photodegradation in a concentration-dependent way, keeping SPF and UVA protection steady after irradiation of up to 30 minimal erythemal doses 12. That is why the two so often share a European formula.
, , ,
Tap an underlined ingredient to see what it does.
How the FDA sees it
In the US, sunscreen is an over-the-counter drug, and the question is framed differently: is a filter “generally recognized as safe and effective” (GRASE)? In its proposed rule of 26 February 2019, the FDA proposed GRASE status for just two filters, zinc oxide and titanium dioxide, at up to 25%. It proposed dropping PABA and trolamine salicylate, and asked for more data on the other twelve, including homosalate, avobenzone, oxybenzone and octocrylene 8. The agency said plainly that this was not a conclusion that those filters are unsafe 8.
The procedure has since changed (the 2020 CARES Act moved monographs to an administrative-order system), but the line-up has not. A proposed order of 24 September 2021 repeated the same three groups; on 10 September 2026 the FDA finalised the removal of PABA and trolamine salicylate, while homosalate and eleven other filters are still awaiting data 9. On 10 June 2026 the FDA did add bemotrizinol to the US monograph 9, the same molecule Europe has long known as Tinosorb S 5.
The most-quoted absorption data come from two FDA-run randomised trials in JAMA. In 2019, 24 volunteers applied sunscreen at 2 mg/cm² to 75% of the body four times a day for four days; plasma levels of all four filters studied passed 0.5 ng/mL on day one 10. In 2020, with 48 participants and six filters, all six passed the threshold after a single application; for homosalate, geometric mean peak concentrations ran from 13.9 to 23.1 ng/mL depending on the spray format 11. Both papers state that the results do not mean people should stop using sunscreen 10,11.
What is known, and what is not
Put the European and American threads together and the picture is less dramatic than the headlines and less settled than the marketing. Filters are absorbed; that is established. Whether they harm people at real-world doses is not established either way, and regulators are covering the gap with cautious limits.
Homosalate reaches the bloodstream under heavy use
Strong evidence
Randomised trial: 0.5 ng/mL exceeded after the first application.11
Endocrine effects of homosalate in humans
Not enough evidence
SCCS: evidence inconclusive and “at best equivocal”.2
Homosalate safety margin at 10% in a body product
Moderate evidence
SCCS calculation: 6.3 against 100 with 18 g applied daily; rests on animal data.2
Tinosorb S stabilises avobenzone
Limited evidence
Laboratory measurements on formulas, no human data.12
Regular sunscreen use lowers melanoma risk
Moderate evidence
One long-term randomised trial; borderline significance overall, a clearer effect for invasive melanoma.13
What to do with the bottle you own
First: do not bin your sunscreen and go out without it. In an Australian trial of 1,621 adults assigned to daily or discretionary sunscreen use, ten years after the trial ended the daily group had 11 new melanomas against 22 13. The drop in all melanomas was borderline significant; for invasive melanomas it was marked 13. Nothing in the filter news changes that.
- Look for Homosalate on the INCI list. A face product bought in the EU after July 2025 already meets the new limit 1.
- If homosalate is in a body product bought outside the EU or before the change, there is no cause for alarm. The SCCS scenario assumes 18 g applied to the whole body every day 2: a cautious, population-wide assumption, not a point at which harm begins.
- If you would rather skip the contested filters, choose formulas built on zinc oxide and titanium dioxide, the only long-established filters the FDA has proposed as safe and effective since 2019 8,9.
- If you prefer light chemical textures, look for avobenzone paired with Tinosorb S, a combination that holds up better in light 12.
- The sunscreen you wear every day, generously, protects you better than the perfect formula sitting on a shelf.
The homosalate story shows regulation working as intended: a question was raised, data were gathered, exposure was recalculated, use was narrowed, and industry got time to reformulate. It is not an alarm. It is a reason to read the label a little more closely.
More from this issue
Dossier9 min read
Red marks, brown marks: what actually fades them
One is pigment, the other blood vessels. Why post-acne marks need different fixes, and how good the evidence for each really is.
Face-off10 min read
Niacinamide vs azelaic acid vs tranexamic acid
Three brighteners, three mechanisms, three different bodies of evidence: what works for melasma, acne marks and rosacea.